Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Krystal Biotech Inc (Krystal Biotech) is a commercial-stage company that focuses on developing genetic medicines for severe, life-threatening, or rare diseases. The company develops and delivers redosable gene therapies. Krystal Biotech's commercial product Vyjuvek (bercolagene telserpavec), is a redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). The company’s products portfolio includes KB407 for Cystic Fibrosis, KB408 for Alpha-1 Antitrypsin Deficiency Lung Disease, KB803 (Ophthalmic B-VEC) for Ocular Complications of DEB, KB801 for Neurotrophic Keratitis, KB111 for Hailey-Hailey Disease, KB707 for Solid Tumors and KB304 for Dynamic Wrinkles of the Décolleté. Krystal Biotech uses its patented gene therapy technology platform based on engineered HSV-1 to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The company operates its own in-house CGMP facilities, Ancoris and Astra to produce its gene therapies. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.
Headquarters
United States of America
Address
Suite 701, 2100 Wharton Street, Pittsburgh, Pennsylvania, 15203
Website
www.krystalbio.com
Telephone
1 412 5865830
No of Employees
295
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KRYS (NASD)
Revenue (2024)
$389.1M
33.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
129.7%
(2024 vs 2023)
Market Cap*
$10.9B
Net Profit Margin (2024)
XYZ
71.5%
(2024 vs 2023)
* As of and is in US$
Krystal Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Vyjuvek (B-VEC- Bercolagene Telserpavec) - Dystrophic Epidermolysis Bullosa (DEB) | Krystal Connect |
| Pipeline | Vyjuvek |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company received MHRA approval in the UK for VYJUVEK to treat dystrophic epidermolysis bullosa. |
| 2025 | Regulatory Approval | In September, the company received approval from the United States Food and Drug Administration for VYJUVEK (beremagene geperpavec-svdt) that expands the VYJUVEK eligible patient population to include dystrophic epidermolysis bullosa patients from birth. |
| 2024 | Regulatory Approval | In February, the company received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy. |
Competitor Comparison
| Key Parameters | Krystal Biotech Inc | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Pittsburgh | New Brunswick | Rahway | New York City | North Chicago |
| State/Province | Pennsylvania | New Jersey | New Jersey | New York | Illinois |
| No. of Employees | 295 | 138,200 | 75,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Krish S. Krishnan | Chairman; Chief Executive Officer; President | Executive Board | 2016 | 61 |
| Kathryn Romano | Executive Vice President; Chief Accounting Officer | Senior Management | 2020 | 44 |
| Suma M. Krishnan | Director; President - Research & Development | Executive Board | 2022 | 61 |
| Laurent Goux | Executive Vice President; General Manager - Europe | Senior Management | - | - |
| David Chien | Senior Vice President - Clinical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer